Viread 300 mg 30 tablets — Made in Ireland — Free Delivery

Viread® tablets are used for the indications listed below.

Tablets of the preparation "Viread" for the treatment of HIV-1-infected patients are prescribed in combination with other antiretroviral preparations.

Viread® tablets are prescribed for the treatment of HIV-1-infected adolescents aged 12 to <18 years with resistance to nucleoside reverse transcriptase inhibitors (NRTIs) or toxicity, which excludes the use of first-line preparations.

The choice of Viread® for the treatment of HIV-1-infected patients treated with antiretroviral preparations should be based on individual viral resistance testing data and / or patient treatment history.

Viread® is intended for the treatment of chronic hepatitis B in adults with:

The preparation "Viread®" is intended for the treatment of chronic hepatitis B in adolescents aged 12 to <18 years with: compensated liver disease, signs of active disease of the immune system, that is, active viral replication, a constant increase in the level of alanine aminotransferase (ALT) in blood serum and histological manifestation of active inflammation and / or fibrosis.

The active ingredient is tenofovir disoproxil fumarate (one coated tablet contains 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil).

Excipients: pregelatinized starch; croscarmellose sodium; lactose monohydrate; microcrystalline cellulose; magnesium stearate; Opadry II White 32K18425 (lactose, monohydrate; hypromellose 2910; titanium dioxide (E 171); triacetin).

hypersensitivity to the active substance or to any of the excipients;

age up to 12 years.

Treatment should be initiated by a physician experienced in the treatment of HIV and / or chronic hepatitis B.

The recommended dose for HIV treatment or for chronic hepatitis B infection is one tablet taken once daily, taken by mouth with food.

Chronic hepatitis B. The optimal duration of treatment is unknown. Conditions for stopping treatment may be:

treatment of patients with a positive reaction to hepatitis B virus antigen (HBeAg) without cirrhosis should continue for at least 6-12 months after confirmation of HBe seroconversion (disappearance of hepatitis B virus antigens and hepatitis B virus DNA with anti-HBe detection) or HBs seroconversion, or to the disappearance of efficiency; after stopping treatment, the level of ALT and hepatitis B virus DNA in the blood serum should be regularly monitored in order to establish any late relapses of viremia;

Treatment of non-cirrhotic hepatitis B virus antigen-negative patients should continue at least until HBs seroconversion or signs of treatment failure appear; in the case of prolonged treatment, lasting more than 2 years, it is recommended to regularly review the treatment to confirm that the chosen therapy remains appropriate for the patient.